CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bristol-Myers Squibb Co is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bristol-Myers Squibb Co
Route 206 And Province Line Road
Phone: (609) 252-4621p:609 252-4621 PRINCETON, NJ  08543  United States Ticker: BMYBMY
Business Summary
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes-YesYes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Christopher S.Boerner 54 4/1/2024 8/28/2018
Executive Vice President, Chief Financial Officer, Member of the Leadership Team David V.Elkins 56 1/1/2019 1/1/2019
President - RayzeBio Organization, Member of the Leadership Team BenjaminHickey 50 1/1/2024 1/1/2024
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
BRISTOL MYERS SQUIBB NEW ZEALAND
BRISTOL-MYERS DE VENEZUELA VENEZUELA
BRISTOL-MYERS SQUIBB FARMACEUTICA L
98 additional Subsidiary records available in full report.

Business Names
Business Name
1096271 BC ULC
345 Park LLC
9643435 Canada Inc.
245 additional Business Names available in full report.

General Information
Number of Employees: 34,100 (As of 12/31/2024)
Outstanding Shares: 2,034,763,197 (As of 3/14/2025)
Shareholders: 29,685
Stock Exchange: NYSE
Federal Tax Id: 220790350
Fax Number: (302) 655-5049


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 17, 2025